New approach aims to make tough cancer treatment more bearable
NCT ID NCT05520723
Summary
This study tested whether giving two preventive medications (loperamide for diarrhea and G-CSF for low white blood cells) alongside the cancer drug sacituzumab govitecan could reduce its common and severe side effects. It involved 50 adults with advanced triple-negative or luminal breast cancer that had stopped responding to prior chemotherapy. The main goal was to see if this combination allowed patients to stay on their cancer treatment longer with fewer treatment interruptions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Arnau de Vilanova
Lleida, Lleida, Spain
-
Hospital Quiron San Camilo- Ruber Juan Bravo
Madrid, Madrid, 28006, Spain
-
Hospital Quirón Valencia
Valencia, Valencia, Spain
-
Hospital Ramón y Cajal
Madrid, Spain
-
Hospital Universitario A Coruña
A Coruña, A Coruna, Spain
-
Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
-
Hospital Universitario Donostia
San Sebastián, Donostia, 20014, Spain
-
Hospital Universitario General de Catalunya
Sant Cugat del Vallès, Barcelona, 08190, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Spain
-
Hospital de Sant Joan Despí - Moises Broggi
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.